CWLXFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends March 31
C21 Investments Inc.
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 12, 2026
Share price
Not available yet
Price, market cap and P/E appear here once daily prices are connected.
C21 Investments Inc. revenue by segment
By business segment
| Revenue | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue |
|---|---|---|---|---|---|---|---|---|
| Nevada [Member] | $32.61M | $28.29M | $28.89M | $32.98M | $33.47M | – | – | 100.0% |
| Corporate [Member] | $0 | $0 | $0 | $0 | $0 | – | – | 0.0% |
| Corporate | – | – | – | – | $0 | $0 | $0 | – |
| Consolidated [Member] | – | $28.29M | $28.89M | $34.11M | $36.13M | – | – | – |
By product or service
By region
| Revenue | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue |
|---|---|---|---|---|---|---|---|---|
| Nevada | – | – | – | – | – | $32.20M | $2.09M | – |
| Oregon | – | – | – | – | – | $5.50M | $500.38K | – |
| OR | – | – | – | – | $2.66M | $5.50M | – | – |
| NV | – | – | – | – | $33.47M | $32.20M | – | – |
From the segment and revenue-disaggregation notes of C21 Investments's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.